Video
Advanced Prostate Cancer Treatment Landscape May Shift Due to New Investigative Treatment
If it were to be approved now, the drug would be used in patients with metastatic castration-resistant prostate cancer who have progressed on an androgen receptor-directed therapy and 1 to 2 taxane-based chemotherapeutics.
In a recent interview with Pharmacy Times, medical oncologist Michael Morris, MD, discussed the newest findings of the phase 3 VISION trial, which is investigating the use of 177Lu-PSMA-617 in patients with advanced prostate cancer, and how this drug could interrupt the typical standard of care. These new findings will be presented at the American Society of Clinical Oncology 2021 annual meeting.
Morris said that based on their current findings, if it were to be approved now, 177Lu-PSMA-617 would be used in patients with metastatic castration-resistant prostate cancer who have progressed on an androgen receptor-directed therapy and 1 to 2 taxane-based chemotherapeutics. He added that some populations of patients could see unique benefits as well, such as patients with DNA-repair defects that developed because of the DNA-damaging impacts of radiation.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
